Abstract
Introduction This study aims to assess the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) in two groups of patients: those who receive lipiodol (referred to as the lipiodol group) and those who do not receive lipiodol (referred to as the control group). Methods From January 2016 through December 2023, 85 patients with advanced hepatocellular carcinoma were enrolled in this retrospective study. In total, 40 patients received HAIC with lipiodol, while 45 patients were given HAIC without lipiodol. The modified response evaluation criteria for solid tumors were used to evaluate the tumor response, which was assessed through an imaging study. The two groups were compared regarding their overall survival, progression-free survival, and safety. Results: The outcomes between the lipiodol group and control group demonstrated no significant difference: the objective response rates (P = 0.066) were 32.5% and 15.6%; the disease control rates (P = 0.556) were 67.5% and 73.3%; the median overall survival times (P = 0.339) were 224 days and 398 days; the median progression-free survival (P = 0.334) times were 191 days and 286 days in the lipiodol group and the control group, respectively. Adverse events also showed no significant difference between the two groups: elevation of total bilirubin (P = 0.834) rates were 40.0% and 37.8%; elevation of alanine aminotransferase (P = 0.191) percentages were 35.0% and 22.2%; and elevation of aspartate aminotransferase values (P = 0.058) were 65.0% and 44.4% in the lipiodol group and the control group, respectively. Conclusions: HAIC without lipiodol was non-inferior to HAIC with lipiodol in the clinical outcome.